

Hubert Serve

Professor, MD



Personal data

Date/Place of birth: May, 07th 1962, in Backnang, Germany
Position: Chair (W3) and Director of the Department of Medicine 2, University Hospital Frankfurt, Goethe-University Frankfurt, Germany
Contact: Department of Medicine 2, Hematology, Oncology, Hemostaseology, Rheumatology, Infectious Diseases; University Hospital Frankfurt, serve@em.uni-frankfurt.de
ORCID:

University Education

1982–1988 Medical School Heidelberg, Germany; Staatsexamen (Medical Licence Examination)
1988 MD thesis, Medical Clinic/Endocrinology, Heidelberg University, Germany (supervisor: Prof. Dr. F. Raue)
2000 Habilitation in Internal Medicine, University of Münster, Germany (Mentor: Prof. Dr. W. E. Berdel)

Scientific Career

1988 - 1990 Physician in Training (Internal Medicine, Hematology/Oncology, Cardiology), *Klinikum rechts der Isar*, Technical University of Munich, Germany
1990 -1991 Physician in Training (Internal Medicine, Hematology/Oncology, Infectious Diseases), Ulm University Hospital, Germany
1991-1994 Postdoctoral Fellow, Division for Molecular Biology, Sloan-Kettering Institute, New York, USA
1994-1997 Physician in Training (Internal Medicine, Hematology/Oncology) University Hospital Benjamin Franklin, Free University of Berlin, Germany
1997-2007 Attending Physician, Hematology/Oncology, University of Münster, Germany
2002-2007 Professor of Medicine, Hematology/Oncology, University of Münster, Germany
2007-present Chair (W3) and Director of the Department of Medicine 2, University Hospital Frankfurt, Goethe-University Frankfurt, Germany
2012-present Coordinator of the Frankfurt/Mainz site of the German Cancer Consortium (DKTK)
2019-present Director of the University Cancer Center Frankfurt (UCT) (Speaker)

Awards, Honors and Activities

1991-1994 Research stipend of the DFG, Memorial Sloan-Kettering Cancer Center, New York, USA
2006-2014 Board Member and (2014) Chair of the of the Expert Committee “Versorgungsmaßnahmen und-Forschung“ of the German Cancer Aid

2010-2018 Co-Coordinator of the LOEWE Center for Cell and Gene therapy
2018-present Coordinator of Frankfurt site of MIRACUM

[Citation record](#) **Publications: 310** **Total citations: 17,961** **h-Index: 66**

Publications

1. Jayavelu AK, Wolf S, Buettner F, Alexe G, Häupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann DC, Wagner S, Donato E, Andresen C, Wilke AC, Zindel A, Jahn D, Splettstoesser B, Plessmann U, Münch S, Abou-El-Ardat K, Makowka P, Acker F, Enssle JC, Cremer A, Schnütgen F, Kurrle N, Chapuy B, Löber J, Hartmann S, Wild PJ, Wittig I, Hübschmann D, Kaderali L, Cox J, Brüne B, Röllig C, Thiede C, Steffen B, Bornhäuser M, Trumpp A, Urlaub H, Stegmaier K, Serve H, Mann M, Oellerich T. The proteogenomic subtypes of acute myeloid leukemia. **Cancer Cell.**;40(3):301-317.e12. (2022)
2. Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Müller-Tidow C, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Frickhofen N, Kullmer J, Kaiser U, Kiani A, Link H, Geer T, Reichle A, Junghanß C, Repp R, Meinhardt A, Dürk H, Klut IM, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Platzbecker U, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia (SAL). Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. **Leukemia**;35(9):2517-2525 (2021)
3. Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. **Lancet Oncol.** 19(12):1668-1679. (2018)
4. Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger M, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T Hoxa9 and Meis1 cooperatively induce addiction to Syk signaling by suppressing miR-146a in acute myeloid leukemia. **Cancer Cell** 31(4): 549-562 (2017)
5. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. **N Engl J Med.** 377(5):454-464. (2017)
6. Schneider C*, Oellerich T*, Baldauf H*, Schwarz S*, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel W, Hartmann W, Wardelmann E, Comoglio F, Hansmann M, Yakunin A, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler O, Cinatl. J SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. **Nat Med.** 23(2): 250-255. (* equal contribution) (2017)
7. Corso J, Pan KT, Walter R, Doebele C, Mohr S, Bohnenberger H, Ströbel P, Lenz C, Slabicki M, Rieger M, Engelke M, Wienands J, Zenz T, Serve H, Urlaub H, Oellerich T Elucidation of tonic and activated B cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival. **Proc Natl Acad of Sci USA**, 7;113(20):5688-93 (2016)
8. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits

- F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. **Lancet Oncol.** 16(16):1691-9 (2015)
9. Oellerich T, Mohr S, Corso J, Beck J, Döbele C, Braun H, Cremer A, Münch S, Wicht J, Oellerich MF, Bug G, Bohnenberger H, Perske C, Schütz E, Urlaub H, Serve H. FLT3-ITD and TLR9 employ Bruton's tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. **Blood** 125(12):1936-47. (2015)
10. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Kramer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G & Berdel WE Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. **J Clin Oncol** 31: 3110-18. (2013)